IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the...
Read More

Still Going Strong After 15,000 Cases: Chicago Prostate Cancer Center Focuses on What is Best for the Patient

Brian J. Moran MD, Medical Director of Chicago Prostate Cancer Center, has been performing brachytherapy procedures to treat prostate cancer since 1990, with over 15,000 brachytherapy treatments to date. In that 27+ years, he has placed a high value in the...
Read More

Leading Urologist Breaks Barriers in Successfully Treating Prostate Cancer with Brachytherapy

Dr. Ron Benoit with the University of Pittsburgh Medical Center is a bit of a maverick. While most urologists lean towards prostatectomy when dealing with a majority of prostate cancer cases, this physician favors brachytherapy—and for good reason. This physician...
Read More

Why we are looking forward to SGO 2017: Breakthroughs in treating gynecologic cancer including Cesium-131 Permanent Interstitial Brachytherapy (PIB)

Isoray is excited to be supporting the upcoming Society of Gynecologic Oncology (SGO) annual meeting, which will be held March 12-15 in National Harbor, Maryland. The SGO meeting serves as a forum on women’s cancer, providing the latest clinical updates and research...
Read More

Pioneer in Prostate Cancer Treatment Leads Data-Driven Approach to Conquer Disease

With over 6000 prostate cancer brachytherapy procedures to date and thousands of IMRT patients, Dr. John Sylvester is a leading authority on research to combat this deadly disease. He recently shared his thoughts on the most effective treatment combinations, and...
Read More

Recent News

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...

Cs-131 is a favorable isotope for use across a wide range of tumors and its dose distribution properties facilitate easy calculation and use in the clinic. Dr. Voichita Bar-Ad

Thomas Jefferson University Hospital

Find A Cesium Pioneer Near You

Doctors going above and beyond against the fight with cancer. Learn More

All News

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...

Bringing Compassion and Hope to Cancer Patients

The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making a difference in the lives of patients diagnosed with different forms of cancer. Isoray Medical, Inc. [NYSE MKT:ISR] has...

Women’s Cancer and Cesium-131 Treatments

Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy...

IsoRay Appoints Thomas LaVoy as CEO

Richland, WA January 14, 2016 – IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the...